Skip to Main Content

Author Details

Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
1991
254
62
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36826816Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.JAMA Netw Open2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36688720Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.J Natl Cancer Inst2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
36688720Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.J Natl Cancer Inst2023
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36826816Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.JAMA Netw Open2023
34844974Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.J Med Genet2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
36210504Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.J Natl Cancer Inst2022
35867953Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.J Clin Oncol2022
35931468Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.Gynecol Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
34844974Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.J Med Genet2022
35077220Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants.J Clin Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36210504Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.J Natl Cancer Inst2022
35867953Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.J Clin Oncol2022
35931468Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.Gynecol Oncol2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
35077220Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants.J Clin Oncol2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
33981016Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.Br J Cancer2021
33599115The GG genotype of erythropoietin rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian subjects with type 2 diabetes mellitus: enemy or ally?Acta Ophthalmol2021
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
32766851Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.J Natl Cancer Inst2021
33599115The GG genotype of erythropoietin rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian subjects with type 2 diabetes mellitus: enemy or ally?Acta Ophthalmol2021
33981016Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.Br J Cancer2021
32766851Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.J Natl Cancer Inst2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32107557Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.J Natl Cancer Inst2020
32284067Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort.Lipids Health Dis2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
  • 1 - 50 of 508

Recommended Authors

Aurelie Vogt
Frederick National Laboratory for Cancer Research (FNLCR), Inc.
Career Start Year 2012
Number of shared co-authors 19
Guanglong Jiang
Indiana University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Eric C Polley
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 52
Zhaoming Wang
St Jude Children's Research Hospital
Career Start Year 2007
Number of shared co-authors 138
Claire Palles
Institute of Cancer and Genomic Sciences, University of Birmingham
Career Start Year 2006
Number of shared co-authors 42
Katia Nones
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 41
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 66
Robert C Onofrio
The Broad Institute of Harvard and MIT
Career Start Year 2005
Number of shared co-authors 22
Laurie Burdett
National Cancer Institute, Frederick National Laboratory for Cancer Research
Career Start Year 2005
Number of shared co-authors 34
Lisa Mirabello
National Cancer Institute
Career Start Year 2005
Number of shared co-authors 38
Ann-Marie Patch
QIMR Berghofer Medical Research Institute
Career Start Year 2005
Number of shared co-authors 68
Xiaohong R Yang
National Cancer Institute
Career Start Year 2003
Number of shared co-authors 115
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 1
Sandya Liyanarachchi
The Ohio State University Comprehensive Cancer Center, Comprehensive Cancer Center
Career Start Year 2002
Number of shared co-authors 7
Sevtap Savas
Memorial University
Career Start Year 1999
Number of shared co-authors 6
Dirce Maria Carraro
AC Camargo Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Tom Walsh
University of Washington
Career Start Year 1996
Number of shared co-authors 16
Anne-Marie Martin
Novartis Pharmaceuticals
Career Start Year 1995
Number of shared co-authors 4
Marbin Pineda
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 26
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 8
Simone Maistro
Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo
Career Start Year 1994
Number of shared co-authors 0
Meredith Yeager
Frederick National Laboratory for Cancer Research
Career Start Year 1993
Number of shared co-authors 82
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 51
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 20
Jeffery P Struewing
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1988
Number of shared co-authors 51
Bharati Bapat
Mt Sinai Hospital
Career Start Year 1988
Number of shared co-authors 16
Ming K Lee
University of Washington
Career Start Year 1988
Number of shared co-authors 9
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 10
Daniela Seminara
National Cancer Institute, 9609 Medical Center Dr
Career Start Year 1981
Number of shared co-authors 87
Mary-Claire King
University of Washington
Career Start Year 1975
Number of shared co-authors 28

Collaborators

Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 165
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 144
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 119
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 113
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 105
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 101
Honglin Song
University of Cambridge
Co-authored papers 100
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 98
Andrew Berchuck
Duke School of Medicine
Co-authored papers 98
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 97
Alice S Whittemore
Co-authored papers 95
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 94
Anna H Wu
University of Southern California
Co-authored papers 92
Jennifer A Doherty
Huntsman Cancer Institute, University of Utah
Co-authored papers 81
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 81
Mary Anne Rossing
Fred Hutchinson Cancer Research Center
Co-authored papers 78
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 78
Douglas F Easton
University of Cambridge
Co-authored papers 76
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 75
Hoda Anton-Culver
University of California irvine
Co-authored papers 73
Brooke L Fridley
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 73
Jan Lubinski
Pomeranian Medical University
Co-authored papers 72
Malcolm C Pike
Memorial Sloan-Kettering Cancer Center
Co-authored papers 71
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 65
Weiva Sieh
Co-authored papers 64
Jonathan Tyrer
Co-authored papers 64
Nicolas Wentzensen
National Cancer Institute, National Institutes of Health
Co-authored papers 63
Ian G Campbell
Co-authored papers 62
Elisa V Bandera
Co-authored papers 57
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 54
Release 1.2